Prognostic stratification of gliomatosis cerebri by IDH1 R132H and INA expression

Journal of Neuro-Oncology

Volumn 105, Issue 2, 2011, Pages 219-224

  Desestret, Virginie ^a   Ciccarino, Pietro ^b,c,d   Ducray, François ^b,c   Crinière, Emmanuelle ^b,c   Boisselier, Blandine ^b,c   Labussière, Marianne ^b,c   Polivka, Marc ^e   Idbaih, Ahmed ^a,b,c   Kaloshi, Gentian ^a   Von Deimling, Andreas ^f   Hoang Xuan, Khe ^a,b,c   Delattre, Jean Yves ^a,b,c   Mokhtari, Karima ^a,b,c   Sanson, Marc ^a,b,c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b CNRS   (France)

^c INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^d UNIVERSITY OF PADOVA   (Italy)

^e HÔPITAL LARIBOISIÈRE   (France)

^f GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Alpha internexin; Gliomatosis cerebri; IDH1; Prognostic markers

Indexed keywords

ALPHA INTERNEXIN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VINCRISTINE;

ARTICLE; BRAIN BIOPSY; BRAIN TUMOR; CANCER GRADING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG RESPONSE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE MUTATION; GLIOMATOSIS CEREBRI; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOLECULAR PATHOLOGY; ONCOGENE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; INTERMEDIATE FILAMENT PROTEINS; ISOCITRATE DEHYDROGENASE; MUTANT PROTEINS; NEOPLASMS, NEUROEPITHELIAL; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 82955235527     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-011-0587-4     Document Type: Article

References (17)

1. N Levin JM Gomori T Siegal 2004 Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide Neurology 63 354 356 15277636 (Pubitemid 38971142)
2. M Sanson S Cartalat-Carel S Taillibert, et al. 2004 Initial chemotherapy in gliomatosis cerebri Neurology 63 270 275 15277619 1:STN:280: DC%2BD2cznsVeksA%3D%3D (Pubitemid 38971125)
3. G Kaloshi S Everhard F Laigle-Donadey, et al. 2008 Genetic markers predictive of chemosensitivity and outcome in gliomatosis cerebri Neurology 70 590 595 18285534 10.1212/01.wnl.0000299896.65604.ae 1:CAS:528: DC%2BD1cXhs1Onurs%3D (Pubitemid 351294636)
4. G Kaloshi R Guillevin N Martin-Duverneuil, et al. 2009 Gray matter involvement predicts chemosensitivity and prognosis in gliomatosis cerebri Neurology 73 445 449 19667319 10.1212/WNL.0b013e3181b163e2 1:STN:280: DC%2BD1MrksFOgtQ%3D%3D
5. F Ducray E Criniere A Idbaih, et al. 2009 Alpha-internexin expression identifies 1p19q codeleted gliomas Neurology 72 156 161 19139367 10.1212/01.wnl.0000339055.64476.cb 1:CAS:528:DC%2BD1MXhsVyktA%3D%3D
6. H Yan DW Parsons G Jin, et al. 2009 IDH1 and IDH2 mutations in gliomas N Engl J Med 360 765 773 19228619 10.1056/NEJMoa0808710 1:CAS:528: DC%2BD1MXitFWru7o%3D
7. MJ van den Bent HJ Dubbink Y Marie, et al. 2010 IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group Clin Cancer Res 16 1597 1604 20160062 10.1158/1078-0432.CCR-09-2902
8. P Metellus B Coulibaly C Colin, et al. 2010 Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis Acta Neuropathol 120 719 729 21080178 10.1007/s00401-010-0777- 8
9. C Houillier X Wang G Kaloshi, et al. 2010 IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas Neurology 75 1560 1566 20975057 10.1212/WNL.0b013e3181f96282 1:CAS:528:DC%2BC3cXhtlGmtrjK
10. D Capper H Zentgraf J Balss C Hartmann A von Deimling 2009 Monoclonal antibody specific for IDH1 R132H mutation Acta Neuropathol 118 599 601 19798509 10.1007/s00401-009-0595-z 1:CAS:528:DC%2BD1MXhtlKitLrK
11. D Capper S Weissert J Balss, et al. 2010 Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors Brain Pathol 20 245 254 19903171 10.1111/j.1750-3639.2009.00352.x 1:CAS:528:DC%2BC3cXpvFOlsA%3D%3D
12. S Camelo-Piragua M Jansen A Ganguly JC Kim DN Louis CL Nutt 2010 Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis Acta Neuropathol 119 509 511 20044756 10.1007/s00401-009-0632-y
13. M Sanson Y Marie S Paris, et al. 2009 Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas J Clin Oncol 27 4150 4154 19636000 10.1200/JCO.2009.21.9832 1:CAS:528:DC%2BD1MXhtF2jtLrP
14. M Seiz J Tuettenberg J Meyer, et al. 2010 Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes Acta Neuropathol 120 261 267 20514489 10.1007/s00401-010-0701-2 1:CAS:528:DC%2BC3cXotVKnsbo%3D
15. C Horbinski J Kofler LM Kelly GH Murdoch MN Nikiforova 2009 Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues J Neuropathol Exp Neurol 68 1319 1325 19915484 10.1097/NEN.0b013e3181c391be 1:CAS:528:DC%2BD1MXhsVOhtLvE
16. F Ducray A Idbaih A de Reynies, et al. 2008 Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile Mol Cancer 7 41 18492260 10.1186/1476-4598-7-41 (Pubitemid 351816762)
17. M Labussière XW Wang Y Marie, et al. 2010 IDH1/IDH2 is systematically mutated in 1p19q codeleted gliomas Neurology 74 1886 1890 20427748 10.1212/WNL.0b013e3181e1cf3a